Asahi Kasei Therapeutics starts Japan Phase II trial of Cresemba in pediatric patients

• Asahi Kasei Therapeutics started a Phase II trial in Japan of isavuconazonium sulfate (Cresemba) for pediatric patients aged 1 to 17.
• Study targets children at risk of deep mycoses, assessing safety profile, pharmacokinetics.
• Cresemba remains unapproved for pediatric use in Japan despite pediatric clearances in several overseas markets.
• Asahi Kasei Therapeutics holds Japan rights; adult Cresemba gained Japan clearance in December 2022, with a 40 mg capsule added in September 2024.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Asahi Kasei Corporation published the original content used to generate this news brief on September 14, 2026, and is solely responsible for the information contained therein.